Holzer Holzer & Fistel, LLC Announces Investigation Into The Proposed Buyout Of Medicis Pharmaceutical Corporation

Holzer Holzer & Fistel, LLC is investigating whether the directors of Medicis Pharmaceutical Corporation (“Medicis” or the “Company”) (NYSE: MRX) complied with their fiduciary duties in approving the proposed acquisition of the Company by Valeant Pharmaceutical International, Inc. According to the Company’s announcement, if the deal closes Medicis shareholders will receive $44.00 for each share of MRX owned. The firm’s investigation seeks to determine, among other things, whether the consideration to be paid to Medicis shareholders is fair and adequate.

Current holders of Medicis common stock with questions concerning their legal rights are encouraged to contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel, Jr., Esq., or Marshall P. Dees, Esq. via email at mfistel@holzerlaw.com, or mdees@holzerlaw.com, or via toll-free telephone at (888) 508-6832.

Holzer Holzer & Fistel, LLC dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.

Copyright Business Wire 2010

If you liked this article you might like

Apple Turns 40 With Little Fanfare as March to Dow 20K Resumes: ICYMI

Medicis Stock Hits New 52-Week High (MRX)

Medicis Pharmaceuticals Corporation (MRX): Today's Featured Drugs Laggard

Medicis Stock To Go Ex-dividend Tomorrow (MRX)

Cramer's 'Mad Money' Recap: The Worse It Gets, the Better